natgillin/translations-raw huggingface dataset:
For the treatment and prevention of fungal infections, the recommended dose of Noxafil tablets or Noxafil solution for infusion is 300 mg twice a day on the first day followed by 300 mg once a day thereafter; the duration of treatment depends on the severity of the disease and the patient's response.
Pri zdravljenju in preprečevanju glivičnih okužb znaša priporočeni odmerek tablet ali raztopine za infundiranje zdravila Noxafil prvi dan 300 mg dvakrat na dan, zatem pa se nadaljuje z odmerkom 300 mg enkrat na dan, pri čemer je trajanje zdravljenja odvisno od resnosti bolezni in bolnikovega odziva.
In oropharyngeal candidiasis, Noxafil oral suspension was as effective as fluconazole.
Pri orofaringealni kandidozi je bila peroralna suspenzija zdravila Noxafil enako učinkovita kot flukonazol.
• terfenadine, astemizole (used for allergy),
• terfenadin, astemizol (ki se uporablja za zdravljenje alergij),
Noxafil oral suspension and tablets have different dosages and should not be used interchangeably.
Peroralna suspenzija in tablete zdravila Noxafil so na voljo v različnih odmerjanjih in niso medsebojno zamenljive.
For additional information, see the package leaflet.
Za več informacij glejte navodilo za uporabo.
Why has Noxafil been approved?
Zakaj je bilo zdravilo Noxafil odobreno?
• halofantrine (used to treat malaria),
• halofantrin (ki se uporablja za zdravljenje malarije),
In another main study involving 350 HIV-infected patients with oropharyngeal candidiasis, Noxafil oral suspension was compared with fluconazole.
V drugi glavni študiji, ki je vključevala 350 bolnikov, okuženih z virusom HIV in orofaringealno kandidozo, so peroralno suspenzijo zdravila Noxafil primerjali s flukonazolom.
• invasive aspergillosis (fungal infection caused by Aspergillus),
• invazivne aspergiloze (vrste glivične okužbe, ki jo povzroča Aspergillus),
Noxafil tablets and solution for infusion must not be used for the treatment of thrush.
Tablete in raztopina za infundiranje zdravila Noxafil se ne smejo uporabljati za zdravljenje ustnega oprha.
The ability to prevent infections was investigated in two additional main studies, where Noxafil oral suspension was compared with fluconazole in 600 stem cell transplant patients and with fluconazole or itraconazole in 602 patients with blood or bone marrow cancer.
Učinkovitost peroralne suspenzije zdravila Noxafil pri preprečevanju okužb so proučevali v dveh dodatnih študijah, in sicer so ga pri 600 bolnikih, ki so imeli presaditev matičnih celic, primerjali s flukonazolom, pri 602 bolnikih s krvnim rakom ali rakom kostnega mozga pa s flukonazolom ali itrakonazolom.
• ergotamine or dihydroergotamine (used to treat migraine),
• ergotamin ali dihidroergotamin (ki se uporablja za zdravljenje migrene),
Noxafil oral suspension is also used as a first-line treatment for ‘thrush', a fungal infection of the mouth and throat due to Candida.
Peroralna suspenzija zdravila Noxafil se uporablja tudi kot zdravilo prve izbire za zdravljenje bolnikov z ustnim oprhom, tj. glivično okužbo ust in žrela, ki jo povzroča Candida.
Patients given the solution for infusion should be switched to Noxafil tablets or oral suspension as soon as the patient's condition allows it.
Bolniki, ki prejemajo raztopino za infundiranje, morajo čim prej, ko njihovo stanje to omogoča, preiti na uživanje tablet ali peroralne suspenzije zdravila Noxafil.
• fusariosis (fungal infection caused by Fusarium),
• fuzarioze (vrste glivične okužbe, ki jo povzroča Fusarium),
For the treatment of fungal infections, with the exception of oral candidiasis, Noxafil oral suspension is taken at a dose of 400 mg (10 ml) twice a day, or 200 mg (5 ml) four times a day in patients who cannot tolerate a meal.
Za zdravljenje glivičnih okužb, razen ustne kandidoze, se peroralna suspenzija zdravila Noxafil jemlje v odmerku 400 mg (10 ml) dvakrat na dan ali 200 mg (5 ml) štirikrat na dan pri bolnikih, ki ne prenesejo zaužitja hrane.
The CHMP concluded that, although the first study compared Noxafil with records of patients who were actually enrolled in that study, the effectiveness of Noxafil was shown.
CHMP je sklenil, da je bila učinkovitost zdravila Noxafil dokazana, četudi so zdravilo v prvi študiji primerjali s poročili bolnikov, ki so dejansko sodelovali v študiji.
In the prevention studies, Noxafil oral suspension was as effective as fluconazole in stem cell transplant patients, with 5% of patients developing an infection in the Noxafil group, and 9% in the comparator group.
V študijah preprečevanja bolezni je bila peroralna suspenzija zdravila Noxafil pri bolnikih s presaditvijo matičnih celic enako uspešna kot flukonazol, in sicer se je v skupini, ki je prejemala zdravilo Noxafil, okužba razvila pri 5 % bolnikov, v primerjalni skupini pa pri 9 %.
For the full list of all side effects reported with Noxafil, see the package leaflet.
Za celoten opis neželenih učinkov, o katerih so poročali pri uporabi zdravila Noxafil, glejte navodilo za uporabo.
For oral candidiasis, Noxafil oral suspension is taken as 200 mg (5 ml) on the first day followed by 100 mg (2.5 ml) once a day for the following 13 days.
Pri ustni kandidozi se prvi dan uporabi peroralna suspenzija zdravila Noxafil v odmerku 200 mg (5 ml), potem pa v odmerku 100 mg (2,5 ml) na dan naslednjih 13 dni.
• coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
• kokcidioidomikoze (glivične okužbe pljuč, ki jo povzroča vdihavanje spor).
Noxafil is an antifungal medicine that contains the active substance posaconazole; it is available as an oral suspension (40 mg/ml), a concentrate (300 mg) for solution for infusion (drip) into a vein and as gastroresistant tablets (100 mg).
Na voljo je v obliki peroralne suspenzije (40 mg/ml), koncentrata (300 mg) za pripravo raztopine za infundiranje (kapalno infuzijo) v veno in gastrorezistentnih tablet (100 mg).
The medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the Noxafil group, and 8% in the comparator groups.
Pri bolnikih z rakom je bilo zdravilo Noxafil učinkovitejše od flukonazola ali itrakonazola - v skupini, ki je prejemala zdravilo Noxafil, se je okužba razvila pri 2 % bolnikov, v primerjalni skupini pa pri 8 %.
What is Noxafil?
Kaj je zdravilo Noxafil?
What is Noxafil used for?
Za kaj se zdravilo Noxafil uporablja?
How does Noxafil work?
Kako zdravilo Noxafil deluje?
How has Noxafil been studied?
Kako je bilo zdravilo Noxafil raziskano?
• quinidine (used for irregular heart beat),
• kinidin (ki se uporablja za zdravljenje motenj srčnega ritma),
How is Noxafil used?
Kako se zdravilo Noxafil uporablja?
For the prevention of invasive fungal infections, Noxafil oral suspension is given at a dose of 200 mg (5 ml) three times a day.
Pri preprečevanju invazivnih glivičnih okužb se uporablja peroralna suspenzija zdravila Noxafil v odmerku 200 mg (5 ml) trikrat na dan. Trajanje zdravljenja je odvisno od bolnikovega stanja.
This summary was last updated in November 2011.
Povzetek je bil nazadnje posodobljen novembra 2011.
In very rare cases, they may be serious or fatal.
V zelo redkih primerih so lahko resni ali povzročijo celo smrt.
If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part
Če želite več informacij, ki temeljijo na priporočilih CVMP, preberite znanstveno razpravo (ki je prav tako del EPAR).
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
Njegov namen je pojasniti, kako je Odbor za zdravila za uporabo v veterinarski medicini (CVMP) ocenil predloženo dokumentacijo, na podlagi katere je oblikoval priporočila glede pogojev uporabe zdravila.
What are the precautions for the person who gives the medicine or comes
Kakšne previdnostne ukrepe mora upoštevati oseba, ki daje zdravilo ali
They disappear once treatment has stopped.
Po končanem zdravljenju izzvenijo.
The European Commission granted a marketing authorisation valid throughout the European Union, for Flexicam on 10 April 2006 and an extension to Flexicam 5mg/ml solution for injection on 9 December 2008.
Evropska komisija je dovoljenje za promet z zdravilom Flexicam, veljavno po vsej Evropski uniji, odobrila dne 10. aprila 2006, podaljšanje dovoljenja za promet z zdravilom Flexicam 5mg/ml raztopina za injiciranje pa 9. decembra 2008.
What benefit has Flexicam shown during the studies?
Kakšne koristi je zdravilo Flexicam izkazalo med študijami?
If the product is swallowed by a person, the advice of a doctor should be sought immediately.
Če oseba zaužije zdravilo nenamerno, se je treba nemudoma posvetovati z zdravnikom.
A study looked at how Flexicam was absorbed and its effects in the body, in comparison with Metacam
V študiji so proučevali absorbiranje zdravila Flexicam ter njegove učinke na telo v primerjavi z zdravilom Metacam
Presentations of Flexicam oral suspension were subsequently not renewed.
Dovoljenja za promet s farmacevtskimi oblikami zdravila Flexicam peroralna suspenzija posledično niso bila podaljšana.
What is the risk associated with Flexicam?
Kakšna tveganja so povezana z zdravilom Flexicam?
The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Flexicam has been shown to be bioequivalent to Metacam 1.5 mg/ml oral suspension.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je menil, da se je zdravilo Flexicam v skladu z zahtevami Evropske unije izkazalo kot biološko enakovredno zdravilu Metacam 1,5 mg/ml peroralna suspenzija.
Flexicam was presented as a pale green oral suspension (1.5mg/ml) for dogs (to be given mixed with food) and a yellow solution for injection (5mg/ml) for dogs and cats.
Zdravilo Flexicam je na voljo kot svetlo zelena peroralna suspenzija (1,5 mg/ml) za pse (ki se zmeša s hrano) in rumena raztopina za injiciranje (5 mg/ml) za pse in mačke.
Flexicam has been investigated in comparison with Metacam which is already authorised in the EU.
Zdravilo Flexicam so primerjali z zdravilom Metacam, ki že ima dovoljenje za promet v EU.
Flexicam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Zdravilo Flexicam vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSAID).
Meloxicam acts by inhibition of prostaglandin synthesis.
Meloksikam deluje tako, da zavira sintezo prostaglandinov.
Flexicam should not be administered to pregnant or lactating animals as the safety of the product has not been established in these cases.
Zdravilo Flexicam se ne sme uporabljati pri brejih živalih ali živalih v obdobju laktacije, ker varnost zdravila v teh primerih ni bila ugotovljena.
Why has Flexicam been approved?
Zakaj je bilo zdravilo Flexicam odobreno?
Flexicam should also not be used in animals suffering from gastrointestinal or hemorrhagic disorders and impaired renal or hepatic function, animals with known hypersensitivity to NSAIDs, and animals less than 6 weeks of age or in cats of less than 2 kg.
Zdravilo Flexicam se ne sme uporabljati pri živalih z obolenji prebavil ali hemoragičnimi obolenji ter pri motnjah jetrne ali ledvične funkcije, živalih z ugotovljeno preobčutljivostjo na nesteroidna protivnetna zdravila ter živalih, mlajših od 6 tednov, ali mačkah, lažjih
Studies have been carried out to prove that Flexicam is ‘bioequivalent' to the reference veterinary medicine: this means that Flexicam is equivalent to Metacam 1.5 mg/ml suspension in the way it is absorbed and used by the body.
Študije so pokazale, da je zdravilo Flexicam „biološko enakovredno“ referenčnemu veterinarskemu zdravilu - to pomeni, da se zdravilo Flexicam v telesu absorbira in uporablja enako kot zdravilo Metacam 1,5 mg/ml suspenzija.
What is Flexicam used for?
Za kaj se zdravilo Flexicam uporablja?
An oral follow-up therapy using meloxicam or other NSAIDs should not be used in cats, as no safe dosage for repeated oral administration has been established.
Pri mačkah zdravljenja ne smete nadaljevati s peroralno obliko meloksikama ali drugega nesteroidnega protivnetnega zdravila, ker pri njih še ni določen varen odmerek za nadaljevalno peroralno zdravljenje.
Flexicam contains meloxicam which belongs to a class of medicines having anti-inflammatory action.
Zdravilo Flexicam vsebuje meloksikam, ki spada v skupino zdravil s protivnetnim delovanjem.
Occasional side effects of Flexicam are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools and apathy (lack of vitality).
Občasni neželeni učinki zdravila Flexicam so enaki kot pri drugih nesteroidnih protivnetnih zdravilih in obsegajo izgubo teka, bruhanje, drisko, kri v blatu in apatijo (pomanjkanje vitalnosti).
As the prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam
Prostaglandini so snovi, ki sprožajo vnetje, bolečino, izločanje tekočine in zvišano telesno temperaturo, meloksikam pa zmanjša
The CVMP concluded that the benefits of Flexicam exceed the risks for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders, reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery in dogs and reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats and recommended that Flexicam be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Flexicam pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišičnoskeletnih obolenjih, lajšanju pooperativne bolečine in vnetja po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah večje od z njim povezanih tveganj, in priporočil, da se za zdravilo Flexicam odobri dovoljenje za promet.
Flexicam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in
Zdravilo Flexicam je učinkovito pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih ter lajšanju pooperativne bolečine po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah
Flexicam is a ‘generic': this means that Flexicam is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam 1.5 mg/ml oral suspension).
To pomeni, da je podobno „referenčnemu veterinarskemu zdravilu“, ki je že bilo odobreno v EU (zdravilu Metacam 1,5 mg/ml peroralna suspenzija).
How does Flexicam work?
Kako je bilo zdravilo Flexicam raziskano?
This can reduce the symptoms of gout.
To lahko zmanjša simptome protina.
The full EPAR for Febuxostat Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Febuksostat Mylan je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Febuxostat Mylan should be started 2 days before chemotherapy and continued for at least 7 days.
Zdravljenje z zdravilom Febuksostat Mylan je treba začeti dva dni pred kemoterapijo in nadaljevati najmanj sedem dni.
The Committee recommended that Febuxostat Mylan be approved for use in the EU.
Priporočil je, da se zdravilo Febuksostat Mylan odobri za uporabo v EU.
Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Adenuric, and do not need to be repeated for Febuxostat Mylan.
Študije o koristih in tveganjih zdravilne učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Adenuric, zato jih ni treba ponoviti za zdravilo Febuksostat Mylan.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Febuxostat Mylan has been shown to have comparable quality and to be bioequivalent to Adenuric.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Febuksostat Mylan primerljivo raven kakovosti kot zdravilo Adenuric ter da mu je biološko enakovredno.
This is a summary of the European public assessment report (EPAR) for Febuxostat Mylan.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Febuksostat Mylan.
This usually reduces blood uric acid levels within two weeks, but the dose can be increased to 120 mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after two to four weeks.
To običajno zniža koncentracijo sečne kisline v krvi v dveh tednih, vendar pa je mogoče v primeru, če ostane koncentracija sečne kisline v krvi po dveh do štirih tednih visoka (nad 6 mg na deciliter), odmerek povečati na 120 mg enkrat na dan.
Because Febuxostat Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Febuksostat Mylan generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
What measures are being taken to ensure the safe and effective use of Febuxostat Mylan?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Febuksostat Mylan?
It works by blocking an enzyme called xanthine oxidase, which is needed to make uric acid in the body.
Deluje tako, da zavira encim, imenovan ksantinska oksidaza, ki je potreben za tvorbo sečne kisline v telesu.
Attacks of gout can still occur during the first few months of treatment, so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Febuxostat Mylan.
V prvih nekaj mesecih zdravljenja še vedno lahko pride do zagonov protina, zato je priporočljivo, da bolnik vsaj prvih šest mesecev zdravljenja z zdravilom Febuksostat Mylan jemlje druga zdravila za njihovo preprečevanje.
This means that Febuxostat Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Adenuric.
To pomeni, da vsebuje enako zdravilno učinkovino in ima enak način delovanja kot referenčno zdravilo Adenuric, ki je že odobreno v Evropski uniji (EU).
As for every medicine, the company provided studies on the quality of Febuxostat Mylan.
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Febuksostat Mylan.
When this happens in the joints and causes pain, it is known as ‘gout'.
Kadar pride do odlaganja v sklepih, ki povzroča bolečino, to imenujemo „protin“ ali „putika“.
For more information about treatment with Febuxostat Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Febuksostat Mylan preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Febuxostat Mylan have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Febuksostat Mylan upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What are the benefits and risks of Febuxostat Mylan?
Kakšne so koristi in tveganja, povezani z zdravilom Febuksostat Mylan?
In patients who are on chemotherapy a reduction in uric acid levels is expected to reduce the risk of tumour lysis syndrome.
Pri bolnikih, ki prejemajo kemoterapijo, naj bi zmanjšanje ravni sečne kisline po pričakovanjih zmanjšalo tveganje za sindrom tumorske lize.
Febuxostat Mylan is available as tablets (80 and 120 mg) and can only be obtained with a prescription.
Zdravilo Febuksostat Mylan je na voljo v obliki tablet (80 in 120 mg), njegovo predpisovanje in izdaja je le na recept.
For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, the recommended dose is 120 mg once a day.
Za preprečevanje in zdravljenje hiperurikemije pri bolnikih, ki prejemajo kemoterapijo, je priporočeni odmerek 120 mg enkrat dnevno.
For practical information about using Febuxostat Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Febuksostat Mylan naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Keeping uric acid levels low for long enough can also shrink tophi.
Vzdrževanje koncentracije sečne kisline na nizki ravni dovolj dolgo lahko zmanjša tudi velikost tofov.
For the treatment of long-term hyperuricaemia, the recommended dose of Febuxostat Mylan is 80 mg once a day.
Pri zdravljenju dolgotrajne hiperurikemije je priporočeni odmerek zdravila Febuksostat Mylan 80 mg enkrat na dan.
Febuxostat Mylan is used in patients who have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones', larger deposits of urate crystals that can cause joint and bone damage).
Zdravilo Febuksostat Mylan se uporablja pri bolnikih, ki kažejo znake odlaganja kristalov, vključno s protinskim artritisom (bolečino in vnetjem v sklepih) ali tofi („kamni“večjimi skupki kristalov urata, ki lahko povzročijo poškodbe sklepov in kosti).
Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys.
Hiperurikemija lahko privede do tvorbe kristalov urata in njihovega odlaganja v sklepih in ledvicah.
Febuxostat Mylan is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are receiving chemotherapy (medicines to treat cancer) and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys).
Zdravilo Febuksostat Mylan se uporablja tudi za zdravljenje in preprečevanje visokih ravni sečne kisline v krvi pri odraslih s krvnim rakom, ki prejemajo kemoterapijo (zdravila za zdravljenje raka) in so izpostavljeni tveganju za sindrom tumorske lize (zapletu zaradi razgradnje rakavih celic, ki povzroči nenadno povečanje sečne kisline v krvi, kar lahko privede do okvare ledvic).
What is Febuxostat Mylan and what is it used for?
Kaj je zdravilo Febuksostat Mylan in za kaj se uporablja?
Febuxostat Mylan contains the active substance febuxostat and is a ‘generic medicine'.
Zdravilo Febuksostat Mylan vsebuje zdravilno učinkovino febuksostat in je „generično zdravilo“.
By reducing the production of uric acid, Febuxostat Mylan can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up.
Z zmanjševanjem tvorbe sečne kisline lahko zdravilo Febuksostat Mylan zniža njeno koncentracijo v krvi in jo vzdržuje na nizki ravni ter tako ustavi kopičenje kristalov.
Therefore, the CHMP's view was that, as for Adenuric, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi enako kot pri zdravilu Adenuric odtehtajo znana tveganja.
Febuxostat Mylan is a medicine used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate' in the blood).
Zdravilo Febuksostat Mylan se uporablja za zdravljenje odraslih z dolgotrajno hiperurikemijo (visokimi koncentracijami sečne kisline ali urata v krvi).
Febuxostat Mylan febuxostat
Febuksostat Mylan febuksostat
It is not intended to provide practical advice on how to use Febuxostat Mylan.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Other information about Febuxostat Mylan
Druge informacije o zdravilu Febuksostat Mylan